Nasdaq
$2.66▲ 8.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $14.2MShares out 5.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 9.23Pre-market26.09.23 13:15filedEFFECTOther#●●●
NewcelX Ltd.
The registration statement filed by NewcelX Ltd. (File No. 333-290516) was declared effective by the SEC on September 22, 2026. This effectiveness allows the company to proceed with the securities offering or capital raising activities outlined in the filing.…more
$2.66+8.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18After-hours26.09.19 05:20POS AMOther
NewcelX Ltd.
NewcelX Ltd. has filed Post-Effective Amendment No. 3 to its Form F-1 registration statement for the resale of up to 500,000 common shares. This filing updates information regarding the potential sale of shares under a $25.0 million common share purchase agreement with Alpha Capital Anstalt entered into on March 31, 2025. The company is not selling any securities itself under this prospectus and will not receive proceeds from the selling shareholder's sales.…more
$2.66+8.13%vs prev closeView filingShare - 9.18After-hours26.09.19 05:156-KKey event
NewcelX Ltd.
NewcelX reported a net loss of $2.9 million for the first half of 2026 in its interim financial statements. The company is currently preparing an IND submission for its lead Type 1 diabetes program, NCEL-101, following a successful Type B Pre-IND meeting with the FDA and its merger with Kadimastem in October 2025.…more
$2.66+8.13%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.28Pre-market26.09.28 21:00#●●●#●●●
NewcelX Advances Type 1 Diabetes Therapy Development
NewcelX is attending a medical congress to discuss the development of its lead Type 1 Diabetes candidate, NCEL-101. While the company has aligned on a regulatory path with the FDA, the program remains in the early stages of clinical preparation.…more
$2.66+8.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 7.31Pre-market26.07.31 22:00
●●●●●●●● ●●●●● ●●●●●●
뉴셀엑스가 기존 주가 대비 20% 높은 가격으로 140만 달러 규모의 사모 유상증자를 단행합니다. 조달된 자금은 제1형 당뇨병 치료제 후보물질인 NCEL-101의 임상 개발 가속화에 사용될 예정입니다.…more
$2.66+8.13%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report